Gur Roshwalb

Partner
aMoon Fund
​​

Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts and deals, manages the due diligence process, and sits on the boards of aMoon Growth portfolio companies AltruBio, BioSplice, KAHR, Mina Therapeutics, and Viracta Therapeutics.
Beginning his career as a practicing physician, Gur understands the urgency driving innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice.
Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Previously, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies.
Gur started his finance career at Piper Jaffray, where he worked as a Vice President and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident.
Gur obtained his MD from the Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and his BA from Columbia University.

Speech title & Synopsis

Strategies for widening the therapeutic window

Companies have focused on all aspects of the ADC—from the antibody design, including biparatopic antibodies, to novel linkers and payloads (including radio isotopes, siRNA or other payloads). Other companies have tried to mimic the specificity of antibodies, with versions of nanoparticles, as one of the fundamental issues with antibodies is the large size and ability to infiltrate solid tumors. Finaly, we believe that focusing on internalization mechanisms is a key for widening the therapeutic window. We will review each of these topics and their efforts to widen the therapeutic window in ADCs.